AGIO Jumps 15% on FDA Priority Review for Sickle Cell Drug

Shares of Agios Pharmaceuticals (AGIO) surged over 14% in morning trading after the FDA accepted its supplemental New Drug Application (NDA) for mitapivat to treat sickle cell disease (SCD). The FDA granted Priority Review, setting a decision deadline of November 1.

Mitapivat is already approved for adults with pyruvate kinase (PK) deficiency and alpha- or beta-thalassemia. The company is now seeking approval for SCD based on a Phase 3 trial that met its primary endpoint of hemoglobin response and key secondary endpoints.

However, the trial did not show a statistically significant reduction in sickle cell pain crises (SCPCs), which are a major symptom of the disease. Despite this, the FDA deemed the data compelling enough to grant an accelerated review.

This is an accelerated approval pathway, meaning full traditional approval depends on the ongoing REIGNITE Phase 3 Confirmatory Trial, with results expected next year at the earliest.

Sickle cell disease affects approximately 100,000 people in the U.S., and current treatment options are limited. If approved, mitapivat could become a standard therapy, significantly expanding Agios' addressable market beyond PK deficiency and thalassemia.

The Priority Review designation signals that the FDA views mitapivat as a potential major advance in SCD treatment. This could lead to faster approval and earlier market entry, boosting Agios' revenue and stock price.

However, the failure to meet the pain crises endpoint is a concern. The FDA's decision will hinge on whether the benefits of hemoglobin improvement outweigh the lack of pain reduction. If the agency requests additional data or delays approval, the stock could face volatility.

Investors should also watch the REIGNITE trial results, which will determine whether mitapivat receives full approval. Positive data could drive further upside, while negative results could lead to restrictions or withdrawal.